Prognostic significance of changes in prostate-specific antigen in patients with metastasis prostate cancer after endocrine treatment

International Urology and Nephrology

Volumn 32, Issue 4, 2001, Pages 659-663

  Furuya, Yuzo ^a   Akakura, K ^a   Tobe, T ^a   Ichikawa, T ^a   Igarashi, T ^a   Ito, H ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN THERAPY; ANTIGEN DETECTION; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PATIENT MONITORING; PREDICTION; PROGNOSIS; PROSTATE CANCER; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CASTRATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0035727773     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014410026495     Document Type: Article

References (15)

1. Carcinoma of the prostate
2. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients
3. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer
4. Serum PSA after antiandrogen therapy
5. Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer
6. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging
7. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan
8. Nonparametric estimation from incomplete observations
9. Regression models and life tables
10. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer
11. Response of prostate specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer
12. Biochemical monitoring of carcinoma of prostate treated with an LHRH analogue (Zoladex)
13. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer
14. Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status?
15. Pattern of progression and survival in hormonally treated metastatic prostate cancer